Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales.
Europe
HIV self-testing
New prevention technologies
Process evaluation
Randomised controlled trial
Trans men
Trans women
UK
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
28
09
2020
revised:
07
12
2020
accepted:
14
12
2020
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
Globally, trans people are disproportionately affected by HIV, but research on strategies to increase testing are limited. SELPHI is a randomised-controlled-trial (RCT) of 10,135 SELPHI recruited using social networking and trans focused social media. Participants were randomised 60/40 to baseline HIVST (Biosure™) (BT) vs no baseline HIVST (nBT); and at 3-months (if completed the survey and reported recent CAI) 50/50 to 3-monthly HIVST (RT) vs no repeat HIVST (nRT). Outcomes were self-reported through online surveys. We conducted a qualitative study of semi-structured peer-led participant interviews ( SELPHI recruited and randomised 118 trans men and trans women (94 trans men, 24 trans women), of whom 20 (16 trans men, 4 trans women) underwent the second randomisation. Median age at baseline was 29 (IQR: 22, 37), 79% were white, 79% were UK born, 37% had degree level education, and 31% had never tested for HIV. 62% ( HIVST significantly increased testing uptake and frequency in trans men and trans people overall, although recruitment and retention of trans women was low. HIVST acceptability was high and indicates easy access to this novel technology may increase HIV testing access for this key population.
Sections du résumé
BACKGROUND
BACKGROUND
Globally, trans people are disproportionately affected by HIV, but research on strategies to increase testing are limited. SELPHI is a randomised-controlled-trial (RCT) of 10,135
METHODS
METHODS
SELPHI recruited using social networking and trans focused social media. Participants were randomised 60/40 to baseline HIVST (Biosure™) (BT) vs no baseline HIVST (nBT); and at 3-months (if completed the survey and reported recent CAI) 50/50 to 3-monthly HIVST (RT) vs no repeat HIVST (nRT). Outcomes were self-reported through online surveys. We conducted a qualitative study of semi-structured peer-led participant interviews (
FINDINGS
RESULTS
SELPHI recruited and randomised 118 trans men and trans women (94 trans men, 24 trans women), of whom 20 (16 trans men, 4 trans women) underwent the second randomisation. Median age at baseline was 29 (IQR: 22, 37), 79% were white, 79% were UK born, 37% had degree level education, and 31% had never tested for HIV. 62% (
INTERPRETATION
CONCLUSIONS
HIVST significantly increased testing uptake and frequency in trans men and trans people overall, although recruitment and retention of trans women was low. HIVST acceptability was high and indicates easy access to this novel technology may increase HIV testing access for this key population.
Identifiants
pubmed: 33681732
doi: 10.1016/j.eclinm.2020.100700
pii: S2589-5370(20)30444-2
pmc: PMC7910695
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100700Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/03
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-1212-20006
Pays : United Kingdom
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Prof. Rodger reports grants from NIHR, during the conduct of the study; Prof. Phillips reports grants from NIHR, during the conduct of the study; Prof. Bonell reports grants from NIHR, during the conduct of the study; Dr. Burns reports grants from NIHR, during the conduct of the study; Prof. Dunn reports grants from NIHR, during the conduct of the study; Prof McCormack reports grants from NIHR, during the conduct of the study; Dr. Lampe reports grants from NIHR, during the conduct of the study; Prof. McCormack reports grants from NIHR, during the conduct of the study; Dr. Speakman reports grants from NIHR, during the conduct of the study; Dr. Witzel reports grants from NIHR, during the conduct of the study; Peter Weatherburn reports grants from NIHR, during the conduct of the study. All other authors report no conflicts of interest.
Références
J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):21193
pubmed: 27431476
Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75
pubmed: 26963756
Int J STD AIDS. 2017 Feb;28(2):133-137
pubmed: 26826160
AIDS Behav. 2014 Jul;18 Suppl 4:S391-5
pubmed: 24986599
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):e89-e96
pubmed: 27798432
AIDS Behav. 2020 Feb;24(2):506-515
pubmed: 31865516
Curr Opin Infect Dis. 2017 Feb;30(1):50-57
pubmed: 27849635
AIDS Care. 2017 Aug;29(8):990-995
pubmed: 28027664
AIDS Behav. 2015 Nov;19(11):1949-65
pubmed: 26054390
Transgend Health. 2018 Dec 28;3(1):239-250
pubmed: 30623022
AIDS Behav. 2016 Apr;20(4):928-38
pubmed: 26511864
Lancet. 2015 Jan 17;385(9964):274-86
pubmed: 25059941
AIDS Patient Care STDS. 2018 Sep;32(9):360-367
pubmed: 30179528
Int J Environ Res Public Health. 2020 Jan 10;17(2):
pubmed: 31936798
J Assoc Nurses AIDS Care. 2009 Sep-Oct;20(5):348-61
pubmed: 19732694
Lancet. 2016 Jul 23;388(10042):412-436
pubmed: 27323919
PLoS Med. 2018 Aug 28;15(8):e1002645
pubmed: 30153265
BMJ Sex Reprod Health. 2020 Apr;46(2):116-125
pubmed: 31666303
J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20779
pubmed: 27431466
BMC Infect Dis. 2018 Oct 23;18(1):531
pubmed: 30352556
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):505-512
pubmed: 29697595
BMC Infect Dis. 2019 Aug 8;19(1):699
pubmed: 31391003
PLoS One. 2016 Sep 09;11(9):e0162713
pubmed: 27611777
HIV Med. 2020 Mar;21(3):189-197
pubmed: 31821698
BMC Med. 2020 Dec 3;18(1):381
pubmed: 33267890
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Int J Transgend. 2015;16(4):209-221
pubmed: 27110227
Lancet. 2016 Jul 23;388(10042):390-400
pubmed: 27323925
Sex Transm Infect. 2018 Aug;94(5):318-319
pubmed: 29899060
J Am Acad Nurse Pract. 2011 Apr;23(4):175-82
pubmed: 21489011
HIV Med. 2020 Oct;21(9):588-598
pubmed: 32776431